Test the efficacy and safety of treatments in mild to moderate COVID-19 patients in low-resource settings
current phase of drug development
updated 5 Jul 2022
The ANTICOV clinical trial responds to the urgent need to identify treatments that can be used to treat mild and moderate cases of COVID-19 early and prevent spikes in hospitalizations that could overwhelm fragile and already overburdened health systems in low- and middle-income countries.
Launched in November 2020 by the ANTICOV consortium, the study is an open-label, randomised, comparative, ‘adaptive platform trial’ that is testing the safety and efficacy of treatments in mild-to-moderate COVID-19 patients. ANTICOV aims to identify early treatments that can prevent progression of COVID-19 to severe disease and potentially limit transmission.
An adaptive platform trial is a flexible and innovative trial design that allows for treatments to be added or removed as evidence emerges.
ANTICOV researchers are actively looking to select the most promising treatments from ongoing global scientific efforts with proof of efficacy, in collaboration with the Access to COVID-19 Tools Accelerator (ACT-A) Therapeutics Partnership, co-convened by Unitaid and Wellcome on behalf of the COVID-19 Therapeutics Accelerator.
Major funding for the ANTICOV consortium is provided by the German Federal Ministry of Education and Research (BMBF) through KfW and by the global health agency Unitaid as part of ACT-A. Early support to launch the initiative was provided by the European & Developing Countries Clinical Trials Partnership (EDCTP), under its second programme supported by the European Union with additional funding from the Swedish government, and the Starr International Foundation, Switzerland.
News & resources
- 5 July 2022 - Brazil joins ANTICOV trial to find early treatments for people with mild-to-moderate COVID-19
- 5 July 2022 - Brasil participa de estudo global que busca tratamento barato para covid em países pobres, BBC News Brasil
- 28 February 2022 - ANTICOV trial finds drug combination nitazoxanide + ciclesonide does not reduce risk of hospitalization in COVID-19 outpatients
- 10 February 2022 - ANTICOV: clinical trial for COVID-19 in low-resource settings to test a new combination treatment
- 21 October 2021 - The ANTICOV clinical trial in Guinea
- 13 September 2021 - Interview de Nathalie Strub-Wourgaft sur la recherche de médicaments contre le COVID-19, France Culture
- 30 July 2021 - ‘A clear demonstration of the capacity in Africa to conduct extremely complex studies’ – Dr John Amuasi on the ANTICOV trial in Ghana
- 29 July 2021 - Recruitment begins in Mozambique for ANTICOV clinical trial of early treatments for COVID-19
- 28 June 2021 - Why Mali joined the ANTICOV clinical trial: A conversation with Dr Samba Sow
- 24 June 2021 - La plus vaste étude clinique sur les cas légers de COVID-19 a été lancée sur le continent, France 24
- 18 June 2021 - A few moments with an ANTICOV investigator: Dr Bernhards Ogutu in Kenya
- 19 May 2021 - AVAREF and ANTICOV: Accelerating regulatory approval for COVID-19 treatments in Africa
- 11 May 2021 - L’essai clinique ANTICOV, Priorité Santé, RFI
- 5 May 2021 - La plus vaste étude en Afrique sur les cas légers de Covid, RTS
- 27 April 2021 - ANTICOV: largest clinical trial in Africa for people with mild COVID-19 to test new drug combination
- 24 November 2020 - Adaptive platform trials for COVID-19 with Dr Roger Lewis
- 24 November 2020 - Lancement du project ANTICOV dans 13 pays africains, Journal Télévisé en Lingala Facile
- 24 November 2020 - Largest clinical trial in Africa to treat COVID-19 cases before they become severe is launched in 13 countries
Get our latest news, personal stories, research articles, and job opportunities.